The company’s stock price has dropped to around $1.38 per share after its IPF therapy trial was stopped for safety.

Fintel reports that on March 4, 2025, Needham downgraded their outlook for Pliant Therapeutics (NasdaqGS:PLRX) from Buy to ...

Fintel reports that on March 3, 2025, Leerink Partners downgraded their outlook for Pliant Therapeutics (NasdaqGS:PLRX) from ...

Pliant Therapeutics ends its Phase 2b IPF trial for bexotegrast, prompting a Needham downgrade to Hold due to limited ...

Citi lowered the firm’s price target on Pliant Therapeutics (PLRX) to $1.50 from $4 and keeps a Neutral rating on the shares. The company ...

Cantor Fitzgerald reinstated coverage of Pliant Therapeutics (PLRX) with a Neutral rating and no price target The company is discontinuing the ...

Pomerantz LLP is investigating claims on behalf of investors of Pliant Therapeutics, Inc ("Pliant" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or ...

Kansas City Life Insurance Company recorded a net loss of $12.6 million or $1.30 per share in the fourth quarter of 2024, down from net income of $49.1 million or $5.07 per share in the fourth quarter ...

While architectural, museum-worthy nail art is a delight to behold and just as fun to wear, some folks are in the camp of ...

The result is the greatest judicial regression in 30 years. After independence, however, the white wigs grew harder to ...

As Meghan’s new Netflix show airs for the first time, Tanya Gold explores the complex, heartbreaking and deeply unhealthy ...

SBK: Hiroyuki Seki: "we have been out of World Superbike 10 years and we are still learning. The tyres have evolved and we ...